Targeting neuroendocrine differentiation for prostate cancer radiosensitization

Abstract

Radiotherapy (RT) is an important primary treatment for low-risk prostate cancer and the standard treatment for high-risk prostate cancer when combined with hormone therapy. Despite that many patients can be cured by RT, several studies suggest that approximately 30-60% of patients with high-risk cancer experience biochemical recurrence within five years after RT, among them 20% of patients die in 10 years. Neuroendocrine differentiation (NED) is a process by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like) cells, and NED is associated with disease progression and treatment failure. Based on our finding that the transcription factor cAMP response element (CREB) is responsible for fractionated ionizing radiation (FIR)-induced NED, we hypothesized that targeting neuroendocrine differentiation can sensitize prostate cancer cells to radiation. During the period of this grant support, we have made the following important discoveries. First, we have demonstrated that FIR-induced NED constitutes two distinct phases: acquisition of radiation resistance during the first two weeks and NED during the second two weeks. Further, we have demonstrated that targeting either phase can sensitize prostate cancer cells to radiation, and targeting both phases is a potent radiation sensitization approach. Second, we have identified PRMT5 as a critical upstream regulator of FIR-induced CREB activation and NED. Similarly, targeting PRMT5 during either of the two phases can sensitize prostate cancer cells to radiation. Third, we have discovered that PRMT5 is a novel epigenetic activator of AR transcription in prostate cancer cells and PRMTT5 expression correlates positively with AR expression in prostate cancer tissues. Fourth, we have generated preliminary data showing that PRMT5 may act as a master epigenetic regulator of IR-induced DNA DSBs.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2017
Accession Number
AD1049886

Entities

People

  • Chang-deng Hu
  • Chih-chao Hsu
  • Chris Suarez
  • Elena Beketove
  • Gyeon Oh
  • Huan-tian Zhang
  • Jake L Owens
  • Jonathon Malola
  • Sarah Kelsey
  • Xuehong Deng
  • Yihang Wu

Organizations

  • Purdue University

Tags

DTIC Thesaurus Topics

  • Anti-Bacterial Agents
  • Biological Sciences
  • Biomedical Research
  • Cell Physiological Processes
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Chemotherapy
  • Colon Cancer
  • Epithelial Cells
  • Gene Expression
  • Genetics
  • Health Services
  • Ionizing Radiation
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Peptides
  • Pharmacology
  • Prostate Cancer
  • Proteins
  • Radiotherapy
  • Therapy
  • Tissues

Fields of Study

  • Biology
  • Medicine

Readers

  • Oncology (Cancer Research).
  • Prostate Cancer Biology.